Physician profile
Mark Shepherd
NPI 1760499867
$17,328.47
in general payments reported to CMS, 2019-2025
61 companies · $2,538 in 2025
The $2,538 reported for 2025 was more than what 80% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,516 · 2020: $2,190 · 2021: $2,586 · 2022: $2,452 · 2023: $2,169 · 2024: $2,877 · 2025: $2,538.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,552 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,552.07 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $2,011.02 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $1,445.00 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $1,191.23 | 2019-2025 | Evenity, Prolia, Repatha |
| Abbott Laboratories | $1,132.61 | 2019-2025 | Freestyle Libre, Freestyle Libre 3, Eterna |
| Insulet Corporation | $1,114.98 | 2019-2025 | Omnipod |
| Xeris Pharmaceuticals, INC. | $1,091.65 | 2020-2025 | Gvoke Hypopen, Recorlev, Keveyis |
| Corcept Therapeutics | $919.11 | 2019-2025 | Korlym |
| Medtronic, INC. | $810.70 | 2021-2025 | Minimed 780g, Intellis Adaptivestim, Minimed 770g |
| Dexcom, INC. | $740.02 | 2019-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $670.58 | 2019-2025 | Ubrelvy, Synthroid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $641.36 | 2019-2025 | Jardiance, Synjardy |
| Sanofi-Aventis U.S. LLC | $613.44 | 2019-2025 | |
| Radius Health, INC. | $430.23 | 2019-2024 | Tymlos |
| Amarin Pharma, INC. | $409.14 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $385.12 | 2022-2024 |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Shepherd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.